利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

42 条记录 (耗时 0.014 秒)

    IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES
    3.
    发明申请
    IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES 审中-公开
    在细胞毒素治疗期间免疫减少神经毒性

    公开(公告)号：WO2011032003A1

    公开(公告)日：2011-03-17

    申请号：PCT/US2010/048472

    申请日：2010-09-10

    申请人： YALE UNIVERSITY ,  VAN DEN POL, Anthony, N.

    发明人： VAN DEN POL, Anthony, N.

    IPC分类号： A61K39/205 ,  A61P35/00

    CPC分类号： A61K39/205 ,  A61K35/13 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/543 ,  A61K2039/585 ,  C12N2760/20232 ,  C12N2760/20234

    摘要： Methods for protecting the brain and other tissues from virus- associated toxicity are provided. Patients are treated with a first immunizing virus prior to administration of a second, therapeutic cytolytic virus. The immunizing virus is preferably administered peripherally, and initiates an adaptive immune response that is sufficient to reduce or prevent the cytovirulence and inflammation caused by the therapeutic virus. The immunizing virus is administered one or more times, preferably at least twice, before administration of the therapeutic virus. The therapeutic virus can be the same virus as the immunizing virus, or a mutant or variant thereof. Preferably the therapeutic virus is an attenuated virus with reduced virulence compared to the immunizing virus.

    摘要翻译： 提供了保护大脑和其他组织免受病毒相关毒性的方法。 在施用第二种治疗性溶细胞病毒之前，用第一免疫病毒治疗患者。 免疫病毒优选在外周施用，并引发足以减少或预防由治疗性病毒引起的细胞毒性和炎症的适应性免疫应答。 在施用治疗性病毒之前，将免疫病毒施用一次或多次，优选至少两次。 治疗性病毒可以是与免疫病毒相同的病毒，或其突变体或变体。 优选地，治疗性病毒是与免疫病毒相比具有降低的毒力的减毒病毒。

    DISPARATE SUICIDE CARRIER CELLS FOR TUMOR TARGETING OF PROMISCUOUS ONCOLYTIC VIRUSES
    9.
    发明申请
    DISPARATE SUICIDE CARRIER CELLS FOR TUMOR TARGETING OF PROMISCUOUS ONCOLYTIC VIRUSES 审中-公开
    用于肿瘤靶向致敏病毒的异种载体细胞

    公开(公告)号：WO2008009115A1

    公开(公告)日：2008-01-24

    申请号：PCT/CA2007/001268

    申请日：2007-07-18

    申请人： JENNEREX BIOTHERAPEUTICS ULC ,  BELL, John Cameron ,  POWER, Anthony Travis

    发明人： BELL, John Cameron ,  POWER, Anthony Travis

    IPC分类号： A61K35/12 ,  A61P35/00 ,  C12N5/06 ,  C12N5/08

    CPC分类号： A61K35/766 ,  A61K47/6901 ,  A61K2039/515 ,  C12N2760/20232

    摘要： The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval.

    摘要翻译： 本发明提供了用溶瘤病毒如VSV治疗肿瘤疾病如癌症的组合物和方法。 载体细胞用于靶向患病组织，并且在靶向间隔期间通过受试者的免疫系统对溶瘤病毒进行遮盖。 在将病毒递送至靶组织后，溶瘤病毒对载体细胞和靶细胞的裂解促进适应性的免疫反应。 可以使用各种各样的不同的载体细胞，与具有宽向性的混杂溶瘤病毒结合使用，其有利于连续治疗，其中新载体不会对针对先前使用的载体安装的适应性免疫应答敏感。 病毒的混杂也有助于溶解同种异体或异种的载体细胞和靶细胞。 载体细胞感染的裂解期分期进行，使得载体在日食阶段施用，并且裂解遵循治疗靶向间隔的结论。

    RECOMBINANT VSV FOR THE TREATMENT OF TUMOR CELLS
    10.
    发明申请
    RECOMBINANT VSV FOR THE TREATMENT OF TUMOR CELLS 审中-公开
    用于治疗肿瘤细胞的重组VSV

    公开(公告)号：WO03005964A3

    公开(公告)日：2003-04-24

    申请号：PCT/US0222146

    申请日：2002-07-11

    申请人： UNIV MIAMI ,  BARBER GLEN

    发明人： BARBER GLEN

    IPC分类号： C12N15/09 ,  A61K35/76 ,  A61K38/00 ,  A61K38/20 ,  A61K38/21 ,  A61K38/45 ,  A61K48/00 ,  A61P1/02 ,  A61P13/08 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K14/54 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N5/22 ,  C12N7/00 ,  C12N7/01 ,  C12N15/20 ,  C12N15/24 ,  C12N15/47 ,  C12N15/57 ,  C12N15/86 ,  C12N15/00 ,  C12N15/63

    CPC分类号： A61K35/766 ,  A61K38/2026 ,  A61K38/208 ,  A61K38/215 ,  A61K38/217 ,  A61K38/45 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/5406 ,  C12N15/86 ,  C12N2760/20232 ,  C12N2760/20243

    摘要： The present invention relates to compositions and methods for the treatment of tumor and/or malignant and/or cancerous cells. The present invention provides VSV vectors comprising nucleic acid encoding a cytokine, such as interleukin or interferon, or a suicide gene, such as thymidine kinase, or other biological protein, such as heat shock protein gp96, or endostatin or angiostatin, wherein said VSV vectors exhibit greater oncolytic activity against the tumor and/or malignant and/or cancerous cell than a wild-type VSV vector. The present invention also provides methods of making such vectors, host cells, expression systems, and compositions comprising such VSV vectors, and viral particles comprising such VSV vectors. The present invention also provides methods for producing oncolytic activity in a tumor and/or malignant and/or cancerous cell comprising contacting said cell with a VSV vector of the present invention. The present invention also provides methods for suppressing tumor growth comprising contacting said tumor with a VSV vector of the present invention. The present invention also provides methods for eliciting an immune response to a tumor cell in an individual.

    摘要翻译： 本发明涉及用于治疗肿瘤和/或恶性和/或癌细胞的组合物和方法。 本发明提供了包含编码细胞因子如白细胞介素或干扰素或自杀基因如胸苷激酶或其它生物蛋白如热休克蛋白gp96或内皮抑素或血管抑素的VSV载体，其中所述VSV载体 与野生型VSV载体相比，对肿瘤和/或恶性和/或癌细胞表现出更大的溶瘤活性。 本发明还提供了制备这样的载体，宿主细胞，表达系统和包含这种VSV载体的组合物以及包含这种VSV载体的病毒颗粒的方法。 本发明还提供在肿瘤和/或恶性和/或癌细胞中产生溶瘤活性的方法，包括使所述细胞与本发明的VSV载体接触。 本发明还提供抑制肿瘤生长的方法，包括使所述肿瘤与本发明的VSV载体接触。 本发明还提供了引发个体中肿瘤细胞的免疫应答的方法。